Phio Pharmaceuticals
PHIO
3 hedge funds and large institutions have $132K invested in Phio Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
40% less funds holding
Funds holding: 5 → 3 (-2)
43% less capital invested
Capital invested by funds: $230K → $132K (-$98K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$34.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$34.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$20K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$13K |
| 4 |
Bank of New York Mellon
New York
|
-$6K |
| 5 |
FC
Ferris Capital
Marlborough,
Massachusetts
|
-$2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PAM
1
Panagora Asset Management
Boston,
Massachusetts
| $34K | – | – | – |
|
|
TSS
2
Two Sigma Securities
New York
| $28K | – | – | – |
|
|
3
Millennium Management
New York
| $16K | +$34.5K | +1 | New |
|
4
Geode Capital Management
Boston,
Massachusetts
| $12K | – | – | – |
|
5
Vanguard Group
Malvern,
Pennsylvania
| $10K | – | – | – |
|
6
Goldman Sachs
New York
| $9K | – | – | – |
|
|
7
Citadel Advisors
Miami,
Florida
| $7K | -$34.5K | -1 | Closed |
|
8
Northern Trust
Chicago,
Illinois
| $6K | – | – | – |
|
9
BlackRock
New York
| $5K | – | – | – |
|
|
RJFSA
10
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| $5K | – | – | – |
|
|
BDWM
11
Brewin Dolphin Wealth Management
Conskleagh, Dublin,
Ireland
| $5 | – | – | – |
|
|
12
UBS Group
Zurich,
Switzerland
| – | -$20K | -1 | Closed |
|
|
13
Bank of New York Mellon
New York
| – | -$6K | – | – |
|
14
Creative Planning
Overland Park,
Kansas
| – | -$1K | – | – |
|
|
FC
15
Ferris Capital
Marlborough,
Massachusetts
| – | -$2K | – | – |
|
|
16
Hudson Bay Capital Management
Stamford,
Connecticut
| – | -$13K | – | – |
|
PHIO Hedge Fund Activity: Q3 2017 in Review
3 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q3 2017, worth a combined $132K — down 43% from $230K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of PHIO and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $34.5K. The largest seller was Citadel Advisors, exiting entirely with an estimated $34.5K sold.
- 3 institutional investors held Phio Pharmaceuticals (PHIO) as of Q3 2017, down from 5 in Q2 2017.
- Funds reported $132K of Phio Pharmaceuticals stock for Q3 2017, down 43% quarter-over-quarter.
- 1 fund opened new Phio Pharmaceuticals positions in Q3 2017 and 2 closed out, a net change of -1 holder.
- The largest Phio Pharmaceuticals buyer in Q3 2017 was Millennium Management, an estimated $34.5K added.
- The largest Phio Pharmaceuticals seller in Q3 2017 was Citadel Advisors, an estimated $34.5K sold.
Based on aggregated 13F filings for Q3 2017.